GlassScriptPhysician profile
Craig S Levoy
NPI 1801232400
$29,938.55
in general payments reported to CMS, 2019-2025
29 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $1,168 · 2021: $3,252 · 2022: $2,356 · 2023: $1,205 · 2024: $109 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,775 · Consulting Fee: $7,405 · Travel and Lodging: $5,090 · Food and Beverage: $1,312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,775.00 |
| Consulting Fee | $7,405.00 |
| Travel and Lodging | $5,089.68 |
| Food and Beverage | $1,311.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $12,866.12 | 2021-2025 | Apretude, Dovato |
| Merck Sharp & Dohme LLC | $10,335.70 | 2019-2025 | Varivax, Recombivax Hb, Enflonsia |
| Novo Nordisk INC | $2,573.32 | 2019-2025 | Rybelsus, Ozempic |
| Biohaven Pharmaceuticals, INC. | $1,489.94 | 2021 | |
| Gilead Sciences, INC. | $484.60 | 2019-2024 | Biktarvy |
| Abbvie INC. | $315.22 | 2019-2022 | |
| Lilly USA, LLC | $242.71 | 2019-2022 | |
| Amarin Pharma, INC. | $173.01 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $170.14 | 2019-2022 | |
| Exact Sciences Corporation | $139.72 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $129.53 | 2020-2022 | |
| Amgen INC. | $129.53 | 2019-2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.90 | 2020-2022 | |
| Janssen Biotech, INC. | $104.81 | 2019-2022 | |
| Inari Medical, INC. | $97.86 | 2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $90.13 | 2019-2021 | |
| Pfizer INC. | $65.80 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.72 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $58.42 | 2019-2021 | |
| Allergan, INC. | $52.27 | 2019-2020 | |
| Eisai INC. | $40.92 | 2021 | |
| Clarus Therapeutics INC. | $37.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.95 | 2022 | |
| Currax Pharmaceuticals LLC | $30.41 | 2021-2022 | |
| Sanofi Pasteur INC. | $26.79 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.67 | 2022 | |
| Janssen Scientific Affairs, LLC | $17.68 | 2021 | |
| Genentech USA, INC. | $15.53 | 2021 | |
| Ethicon US, LLC | $14.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Levoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.